We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
In May of that year, Pfizer signed an expanded licensing deal with Aurobindo to acquire the rights to 55 solid oral dose products and five sterile injectable products for patients in more than 70 emerging market countries.